Clarus Therapeutics Holdings Inc. CRXT Stock Price has been trying to recover since it’s IPO high of almost $10. Wondering why this stock is having such a hard time and if it can break the overall trend?
Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!
Before we get started, I wanted to introduce myself to you. Hi 🙋♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.
I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.
What do I mean by big winners?
Stocks that move more than 100% in a month! CRXT Stock Price could?
Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!
The article is HERE where I shine a spotlight on trending stocks and breakout stocks!
Now, let’s go over some of the basic information on this stock before we get in the technical analysis
Clarus Therapeutics Holdings Inc. Company Information
Company Name: Clarus Therapeutics Holdings Inc.
Clarus Therapeutics Holdings Company Summary:
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. the company’s first commercial product is JATENZO. It is headquartered in Northbrook, IL.
Clarus Therapeutics stock price is due to News?
March 16, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO (testosterone undecanoate) oral softgel capsules for the treatment of adult hypogonadal men with chronic kidney disease (CKD). Clarus expects to announce results from the trial in the first half of 2023.
CRXT 5 Day Chart
CRXT Stock Price Technical Analysis:
Let’s go over 4 critical factors in regards to a trending stock.
The volume, which is basically demand of a stock is not consistent! However, due to the news, it is heavily traded.
The news, is about as good as you can get!
The chart, it WAS bullish but it went up 85% in today and is now pulling back.
The fundamentals, the vertical is a very profitable one!
I believe Clarus Therapeutics stock could be a good one but not right now. I’m putting it on my watchlist and getting familiar with it, waiting for the right time. After this pullback it will consolidate and I will be watching it!
Sign up for our newsletter 👇👇👇 to get the latest HOT stocks and trending stocks!